Skanska announces decreased scope for facility in Everett, Washington, USA, worth USD 49M, about SEK 510M

Skanska announces that Pfizer has reduced the scope of work on its 25,000 square-meter biomanufacturing facility in Everett, Washington, USA, which Skanska previously was contracted to construct. The order reduction amounts to USD 49M, about SEK 510M, which will be deducted from the US order bookings for the first quarter 2024.

The initial contract with Seagen, who recently was acquired by Pfizer, was worth USD 215M, about SEK 2.2 billion, and was announced August 4, 2023.

For further information please contact:

Daniela Arellano, Communications Director, Skanska USA, tel +1 213 317 4977

Andreas Joons, Press Officer, Skanska AB, tel +46 (0)10 449 04 94

Direct line for media, tel +46 (0)10 448 88 99

This and previous releases can also be found at www.skanska.com.

Skanska Group uses its knowledge and foresight to shape the way people live, work, and connect. We are one of the world’s largest project development and construction companies, with 2023 revenue totaling SEK 157 billion. We operate across select markets in the Nordics, Europe and USA. Together with our customers and the collective expertise of our approximately 27,000 teammates, we create innovative and sustainable solutions that support healthy living beyond our lifetime.